Lucien Nedzi, MD
Enriched profileProgram Director · University of Tennessee Health Science Center
Lucien Nedzi is Program Director at University of Tennessee Health Science Center. OpenAlex indexes 107 publications with 4,848 citations (h-index 29); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 25 Oct 2026
Overview
Updated 27 Oct 2026
Lucien Nedzi, M.D., is Program Director at University of Tennessee Health Science Center. The public record shows 107 publications with 4,848 citations (h-index 29), centered on Advanced Radiotherapy Techniques, Brain Metastases and Treatment, Head and Neck Cancer Studies. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 2 companies.
- Top research focus: Advanced Radiotherapy Techniques
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 50.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 26 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer
Sponsor: University of Texas Southwestern Medical Center
- Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck
Sponsor: University of Texas Southwestern Medical Center
Industry payments
Updated 26 Oct 2026
2 companies reported payments to CMS in program years 2023–2023. These are public disclosures, not judgments. The latest:
- Elekta, Inc.Program year20231 payment
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroid100%Dexamethasone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 26 Oct 2026
30 congress contributions (2004–2020) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical Trial
ASTRO Annual Meeting
ASTRO2020Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
Journal of the National Comprehensive Cancer Network
2023 - Radiotherapy (RT) Dose-intensification (DI) Using Intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM): Preliminary Results of NRG Oncology BN001
International Journal of Radiation Oncology*Biology*Physics
2020 - Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases
International Journal of Radiation Oncology*Biology*Physics
2020
Most-cited works
by citation count (OpenAlex)- 01Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerArticle1,050 citations2017
- 02Stereotactic Body Radiation Therapy for Operable Early-Stage Lung CancerArticle367 citations2018
- 03
- 04
- 05NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022Article238 citations2023
Network
Updated 26 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cme.utsouthwestern.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uthsc.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Csaba Kovesdy, MD
University of Tennessee Health Science Center
Samuel Dagogo-Jack, MD
University of Tennessee Health Science Center
Lucas Elijovich, MD
University of Tennessee Health Science Center
Carmine Zoccali
University of Tennessee Health Science Center
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
Timothy Cloughesy, MD
Ronald Reagan UCLA Medical Center